Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes

UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.endPage3272
UDC.grupoInvInvestigación en Microbiología (INIBIC)
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue12
UDC.journalTitleJournal of Antimicrobial Chemotherapy
UDC.startPage3265
UDC.volume80
dc.contributor.authorBlanco Martín, Tania
dc.contributor.authorGuzmán-Puche, Julia
dc.contributor.authorHernández-García, Marta
dc.contributor.authorMuñoz-Rosa, Montserrat
dc.contributor.authorElías-López, Cristina
dc.contributor.authorRiazzo, Cristina
dc.contributor.authorTorre-Cisneros, Julián
dc.contributor.authorArca-Suárez, Jorge
dc.contributor.authorCausse, Manuel
dc.contributor.authorBou, Germán
dc.contributor.authorCantón, Rafael
dc.contributor.authorMartínez-Martínez, Luis
dc.date.accessioned2026-03-05T08:04:06Z
dc.date.available2026-03-05T08:04:06Z
dc.date.issued2025-09-29
dc.description.abstract[Abstract] Objectives: To generate in vitro ceftazidime-avibactam-resistant mutants derived from Klebsiella pneumoniae producing OXA-48 or OXA-48 derivatives OXA-131 and OXA-232 carbapenemases, to define their antimicrobial susceptibility phenotype and to analyse mutations potentially involved in resistance to ceftazidime-avibactam. Methods: Mutants were obtained by plating overnight bacterial cultures on Mueller-Hinton agar plates containing increasing concentrations of ceftazidime-avibactam (0.5/4-32/4 mg/L). MICs were determined using Sensititre™ DKMNG panels. Whole-genome sequencing of 8 parental strains and 31 mutant derivatives was performed with Illumina. Results: All parental strains were susceptible to ceftazidime-avibactam (MIC ≤ 0.5/4-2/4 mg/L) and either susceptible or resistant to meropenem (MIC 0.5 to >16 mg/L) and imipenem (MIC ≤ 0.5 to >16 mg/L). MICs of ceftazidime-avibactam for the mutants increased up to 4 to >16 mg/L, while MICs of meropenem and imipenem for most mutants either increased up to >16 mg/L or remained unchanged. Whole-genome sequencing of the mutants identified alterations in genes coding for proteins related to AcrAB-TolC (AcrB, AcrR), PBPs (PBP2, PBP3), porins (OmpK36, EnvZ) or the stress or stringent responses (RseB, CpxA, SpoT). No mutations were detected in genes coding for OXA-48-like enzymes or other β-lactamases. Conclusions: Ceftazidime-avibactam can select in vitro mutants of OXA-48-like carbapenemase-producing K. pneumoniae resistant to this combination and, in some cases, also to carbapenems. No mutations related to ceftazidime-avibactam resistance were found in genes coding OXA-48-like enzymes, but they were detected in genes related to active efflux, PBPs, permeability or proteins of the stress and stringent responses.
dc.description.sponsorshipThis study was supported by Instituto de Salud Carlos III (projects PI20/01749 to L M-M and PI24/01449 to MH-G) and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC; CB21/13/00049, CB21/13/00055, CB21/13/00084), integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–16 and funded by the Instituto de Salud Carlos III-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) ‘A way of making Europe.’ T. B.-M. was supported by a grant from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for a stay at the Service of Microbiology, University Hospital Ramón y Cajal, Madrid, Spain, and by the Río Hortega programme (Instituto de Salud Carlos III, CM23/00095). MH-G is supported by a postdoctoral contract by CIBERINFEC (CB21/13/00084). CE-L is supported by a predoctoral contract by CIBERINFEC (CB21/13/00049).
dc.identifier.citationBlanco-Martín T, Guzmán-Puche J, Hernández-García M, Muñoz-Rosa M, Elías-López C, Riazzo C, Torre-Cisneros J, Arca-Suárez J, Causse M, Bou G, Cantón R, Martínez-Martínez L. Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes. J Antimicrob Chemother. 2025 Dec 2;80(12):3265-3272.
dc.identifier.doi10.1093/JAC/DKAF360
dc.identifier.issn1460-2091
dc.identifier.urihttps://hdl.handle.net/2183/47586
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.urihttps://doi.org/10.1093/JAC/DKAF360
dc.rightsThis is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The version of record is available online at Oxford Academic web.
dc.rights.accessRightsembargoed access
dc.subjectAnti-bacterial agents
dc.subjectAzabicyclo compounds
dc.subjectCeftazidime
dc.subjectDrug resistance, Bacterial
dc.subjectKlebsiella pneumoniae
dc.subjectbeta-Lactamases
dc.titleMechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes
dc.typejournal article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
BlancoM_Mechanisms_2025.pdf
Size:
337.4 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
BlancoM_Mechanisms_2025_Suppl.docx
Size:
325.95 KB
Format:
Microsoft Word XML
Description:
Supplementary data